Synergic effects of sorafenib combined with sulforaphane against hepatocellular carcinoma cells in vit ro / 药学实践杂志

ABSTRACT

Objective To investigate the synergic ratio of sorafenib (SO) and sulforaphane (SF) against the hepatocellu‐lar carcinoma cell line HepG2 in vitro .Methods The synergic effect of SO combined with SF against HepG2 cells was deter‐mined by the CCK8 assay (the synergic effect was determined by combination index (CI) valueCI>1 .1 ,antagonistic;0 .9<CI<1 .1 ,additive;CI<0 .9 ,synergic) .The effectiveness of the synergic effect of the synergic ratio was confirmed by the An‐nexinV‐FITC apoptosis experiment and colony formation assay .Results The CCK‐8 assay showed that SO combined with SF at the molar rate of 1∶1 ,1∶10 and 1∶20 exhibited strong antagonism (CI>1 .1) ,whereas 20∶1 ,5∶1 and 1∶5 ratio resul‐ted in synergistic activity (CI<0 .9) .Furthermore ,10∶1 ratio acted as an additive effective (0 .9<CI<1 .1) .The number of colony formation (14 .66 2 .08) of the group treated with SO combined with SF at 5∶1 synergistic ratio was significantly lower than that of the group treated with after SO combined with SF at 1∶1 antagonistic ratio (31 .33 4 .16) (P<0.01) .The early and late apoptosis rate of HepG2 cells (21 .71 ± 6 .06) of the group treated with SO combined with SF at 5∶1 synergistic ratio was significantly higher than that of the group treated with SO combined with SF at 1∶1 antagonistic ratio(6 .64 ± 0 .311)(P<0.01) .Conclusion SO combined with SF at the molar rate of 5∶1 can synergistically inhibit the growth of hepatocellular car‐cinoma cell line HepG2 in v itro .